These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12893525)

  • 1. Species and gender differences in the formation of an active metabolite of a substituted 2,4-thiazolidinedione insulin sensitizer.
    Beconi M; Mao A; Creighton M; Hop CE; Chiu SH; Eydelloth R; Franklin R; Tang F; Yu N; Vincent S
    Xenobiotica; 2003 Jul; 33(7):767-87. PubMed ID: 12893525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
    Prueksaritanont T; Balani SK; Dwyer LM; Ellis JD; Kauffman LR; Varga SL; Pitzenberger SM; Theoharides AD
    Drug Metab Dispos; 1995 Jul; 23(7):688-95. PubMed ID: 7587955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans.
    Rodrigues AD; Ferrero JL; Amann MT; Rotert GA; Cepa SP; Surber BW; Machinist JM; Tich NR; Sullivan JP; Garvey DS
    Drug Metab Dispos; 1994; 22(5):788-98. PubMed ID: 7530622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide.
    Kochansky CJ; Xia YQ; Wang S; Cato B; Creighton M; Vincent SH; Franklin RB; Reed JR
    Drug Metab Dispos; 2005 Dec; 33(12):1894-904. PubMed ID: 16183782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
    Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
    Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs.
    Zhang D; Raghavan N; Chen SY; Zhang H; Quan M; Lecureux L; Patrone LM; Lam PY; Bonacorsi SJ; Knabb RM; Skiles GL; He K
    Drug Metab Dispos; 2008 Feb; 36(2):303-15. PubMed ID: 17984286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.
    Liu L; Halladay JS; Shin Y; Wong S; Coraggio M; La H; Baumgardner M; Le H; Gopaul S; Boggs J; Kuebler P; Davis JC; Liao XC; Lubach JW; Deese A; Sowell CG; Currie KS; Young WB; Khojasteh SC; Hop CE; Wong H
    Drug Metab Dispos; 2011 Oct; 39(10):1840-9. PubMed ID: 21742900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
    Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
    Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.
    Albrecht W; Unger A; Nussler AK; Laufer S
    Drug Metab Dispos; 2008 May; 36(5):894-903. PubMed ID: 18268076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data.
    Iwatsubo T; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Nov; 283(2):462-9. PubMed ID: 9353358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biotransformation of the ergot derivative CQA 206-291 in human, dog, and rat liver slice cultures and prediction of in vivo plasma clearance.
    Vickers AE; Connors S; Zollinger M; Biggi WA; Larrauri A; Vogelaar JP; Brendel K
    Drug Metab Dispos; 1993; 21(3):454-9. PubMed ID: 8100501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species differential stereoselective oxidation of a methylsulfide metabolite of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl)phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor dual agonist.
    Karanam BV; Welch CJ; Reddy VG; Chilenski J; Biba M; Vincent S
    Drug Metab Dispos; 2004 Oct; 32(10):1061-8. PubMed ID: 15229170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: a comparison with human liver microsomes.
    Quintieri L; Fantin M; Palatini P; De Martin S; Rosato A; Caruso M; Geroni C; Floreani M
    Biochem Pharmacol; 2008 Sep; 76(6):784-95. PubMed ID: 18671948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
    Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolites of [(14)C]-5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3, 6-tetrahydropyridine in mice, rats, dogs, and humans.
    Christensen EB; Andersen JB; Pedersen H; Jensen KG; Dalgaard L
    Drug Metab Dispos; 1999 Nov; 27(11):1341-9. PubMed ID: 10534320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
    Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
    Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro metabolism of a new oxazolidinedione hypoglycemic agent utilizing liver microsomes and recombinant human cytochrome P450 enzymes.
    Agrawal AK; Hop CE; Pang J; Silva Elipe MV; Desai RC; Leung KH; Franklin RB
    J Pharm Biomed Anal; 2005 Feb; 37(2):351-8. PubMed ID: 15708677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.